Applications for the 2021 Accelerator programme are officially open.

Opening for its third cohort, the P4 scaling programme seeks to support the world’s leading precision medicine startups. We want every company within precision medicine to apply. To gain the full benefit from this programme, we recommend that companies:

• Work in the area of Precision Medicine*
• Be early to mid-stage medical device, diagnostic or digital health companies 
• Have not yet closed a Series B
• Be data-driven
• Be able to demonstrate their route to market within a timeframe of 12 to 18 months
• Have already received seed/grant funding
• Show team credibility (at least three members with complimentary and relevant expertise)
• Have Data Scientist involvement 
• Use AI 

*Precision (aka personalised) medicine is an approach that will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.

Programme

The P4 programme is led by Professor Phil Beales, Chair of the UCL Institute of Precision Medicine, Professor of Medical and Molecular Genetics at the UCL Great Ormond Street Institute of Child Health and UCL Partners. It is further supported by Capital Enterprise, London’s startup experts.

Cross-faculty support led by the UCL Institute for Precision Medicine, leverages the talent pool of academics at UCL and its partners. Capital Enterprise has experience of supporting and scaling tech SMEs as well as providing access to unique funding streams to ensure SMEs thrive. 

The delivery of precision medicine requires the academia, healthcare and industry sectors to work together. Accordingly, P4 Precision Medicine Accelerator offers a 6 to 12 month scale up programme connecting your company with all these different sectors to create a clear innovation pathway.

Together with strategic partners, participants benefit from dedicated workshops, one-to-one expert advice, industry and academic tech expertise, regulatory pathway support, testbeds and trial opportunities, specialised investor introductions, access to key decision makers and 6 months of co-working space.

At the end of the programme each company will have the chance to present to industry and investors to increase traction and pique investors interest for the next round of investment. Once the programme ends, as P4 alumni, companies will be able to carry on with participation in clinical trials and R&D with partners, as well as access industry events, focused networking events, and other scale-up opportunities.

Why Join

Since its inception the P4 Precision Medicine Accelerator programme has supported its portfolio companies with their raises totalling £30m+, helped with numerous grant applications and facilitated over 20 collaborations so far including hospitals, industry and clinicians.

P4 Precision Medicine Accelerator's 60+ mentors have been invaluable in helping with clinical insight, product design, go-to-market strategy, scaling, manufacturing, regulation and adoption into the NHS and national/international healthcare systems.

Some recent achievements in 2020

Lifebit launched a next-generation genomic research platform dedicated to the COVID-19 response together with Amazon Web Services and Genomics England. Assisted Motilent with the recent installation of their new product into Great Ormond Street Hospital and UCLH funded by a recently awarded prestigious UKRI grant. 2020 cohort member My Personal Therapeutics opened a new drug-screening facility in The West Works, White City Place. P4 aided M2JN’s pivot to help tackle COVID-19.

For a full list of P4 alumni, please visit the website.

How to apply

If you would like to benefit from the expertise of P4 and its partners to scale-up faster and achieve great success, apply to the 2021 P4 Precision Medicine Accelerator programme directly through the website here or here.